Navigation Links
Medicare beneficiaries substantially more likely to use brand-name drugs than VA patients
Date:6/11/2013

PITTSBURGH, June 10, 2013 Medicare beneficiaries with diabetes are two to three times more likely to use expensive brand-name drugs than a comparable group of patients treated within the VA Healthcare System, according to a nationwide study by researchers from the University of Pittsburgh, VA Pittsburgh Healthcare System and Dartmouth College.

Spending in Medicare Part D would have been an estimated $1.4 billion less in 2008 if brand-name and generic drug use matched that of the VA for the medications studied. The report, the first large-scale comparison of prescription drug use between Medicare Part D and the VA, is online and will be published in the print edition of the Annals of Internal Medicine on July 16.

"Our study shows that we can make a big dent in Medicare spending simply by changing the kinds of medications people are using and physicians are prescribing without worrying about whether the government should or should not negotiate drug prices," said lead author Walid Gellad, M.D., M.P.H., an assistant professor in the Pitt Graduate School of Public Health's Department of Health Policy and Management and Pitt's School of Medicine. "The levels of generic use found in the VA are attainable, and they are compatible with high quality care."

The study was jointly funded by the VA, National Institutes of Health (NIH) and Robert Wood Johnson Foundation.

Dr. Gellad and his colleagues analyzed 2008 data for over 1 million Medicare beneficiaries and 500,000 veterans to compare prescription use between Medicare and the VA, focusing on diabetes, cholesterol and blood pressure medications.

Medicare and the VA have a significantly different approach to drug prescribing. Medicare contracts with more than 1,000 private insurance companies, each using a distinct formulary and cost-sharing arrangement for prescribing drugs. The VA uses a single formulary and all veterans have the same cost-sharing arrangement.

Brand-name drugs cost considerably more than generic medications because the distributors of generics generally are not paying the cost of drug development, brand protection and marketing. In a chronic condition like diabetes, there is a broad range of available therapies with widely diverging costs, some of which can be lessened by using a generic medication rather than its brand-name counterpart.

Of the four medication groups commonly used by patients with diabetes, the researchers found that Medicare beneficiaries were more than twice as likely as VA patients to use brand-name drugs in almost every region of the country.

"We're not suggesting that Medicare turn into a VA system, nor do we believe that brand-name drugs have no role in improving health," said Dr. Gellad, also a primary care physician. "This study is about how we can manage our limited resources while maintaining high quality care. The VA shows us that it can be done for prescription drugs. Going forward, we need to understand whether these differences in prescription use have changed, if at all, from 2008 to present."


'/>"/>

Contact: Cyndy McGrath
mcgrathc3@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. Parker Waichman LLC Applauds Seniors for their Role in Helping to Recover $14.9 billion in Medicare Fraud over the Past Four Years
2. Skipping Meds May Raise Odds of ER Visits for Certain Medicare Patients
3. June 6 Webinar Offers Winning Medicare Advantage Go-to-Market Strategies for 2014
4. Vein Specialties Now Accepting Medicare Patients
5. Private insurers Medicare Advantage plans cost Medicare an extra $34.1 billion in 2012
6. Government Data on Extreme Medicare Health Care Price Discrepancies Only Part of the Picture for Most Americans
7. Proposed Medicare Essential plan estimated to save $180 billion over 10 years
8. Aeroflow Healthcare, Inc. Wins 456 Medicare Competitive Bids; Now Looking at Subcontractors
9. Hospitals measure up for Medicare reimbursement
10. 1 in 4 colonoscopies in Medicare patients found to be potentially inappropriate
11. Medicare Spending Not Linked to Longer Cancer Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: